We read with interest the article by Mulè et al., 1 which explores the issue of the potential influence of gender on the relationship between the metabolic syndrome and and left ventricular (LV) mass. The Authors conclude that gender has no discernible effect on the above relation.
Apparently, these findings are in contrast with data from a large cohort of 3266 hypertensive subjects, in which the impact of the metabolic syndrome on LV mass was 70% greater in women than in men, 2 and with a study carried out by our group in 612 untreated hypertensive subjects, in which the increase in LV mass in the subjects with the metabolic syndrome was found to be greater in women than in men. 3 Indeed, in our study men with the metabolic syndrome had a significant 9% increase in LV mass index than men without the syndrome (50.3 vs 46.1 g Â m À2.7 , P ¼ 0.002), whereas this difference was as large as 24% in women (49.5 vs 40.0 g Â m À2.7 , Po0.001), and gender was found to be a significant effect modifier of the relation between the metabolic syndrome and LV mass. 3 However, a closer look at the data by Mulè et al. 1 shows that the percent increase in LV mass in the subjects with the metabolic syndrome was more pronounced among women ( þ 27%) than among men ( þ 16%). Although not significant, the effect of the interaction term 'gender Â metabolic syndrome' bordered statistical significance (P ¼ 0.10, in a multivariate model). It is worth mentioning that about half of the 475 subjects examined by Mulè et al. 1 had been receiving antihypertensive drug treatment up to 2 weeks before the study, and the effect of antihypertensive treatment on LV mass might have played a confounding role. Indeed, in the subgroup of 248 never-treated patients, the gender-specific difference was even greater ( þ 34.2% in women, þ 19.5% in men). Even if the smaller sample size, as compared with the studies by Cuspidi et al. 2 and Schillaci et al., 3 might limit the statistical power of the study, we would suggest the authors to formally test the hypothesis of a gender effect in this subgroup, one not subjected to the confounding effect of drug treatment.
More in general, the results of the above studies [1] [2] [3] provide concordant evidence that LV mass, an important predictor of cardiovascular complications in hypertension, 4 is increased in both men and women with the metabolic syndrome. In addition, we believe that, on the whole, they also suggest that the effect of the metabolic syndrome might be greater in women than in men, although the effect might not be statistically significant in some of the studies. 
